ALEXANDRIA, Va., June 6 -- United States Patent no. 12,281,175, issued on April 22, was assigned to Amgen Inc. (Thousand Oaks, Calif.) and Amgen Research (Munich) GmbH (Munich).
"Binding molecules for BCMA and CD3" was invented by Peter Kufer (Munich), Tobias Raum (Munich), Patrick Hoffmann (Munich), Roman Kischel (Munich), Ralf Lutterbuese (Munich), Doris Rau (Munich), Paul Adam (Munich), Eric Borges (Munich), Barbara Hebeis (Munich) and Susanne Hipp (Munich).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 o...